Search results
9 lip 2020 · The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (NCT01179048, ClinicalTrials.gov) has been described elsewhere . Patients with type 2 diabetes and high CV risk underwent double-blind randomization to daily liraglutide versus placebo in addition to existing care.
28 lip 2016 · In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the...
3 paź 2018 · LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 diabetes mellitus at high cardiovascular risk on standard of care randomized to liraglutide versus placebo.
LEADERS Magazine Online -Past Issues. July, August, September 2024: April, May, June 2024: January, February, March 2024
Clinical Leader offers the latest expert insights, trends, and thought leadership in clinical research that enables pharmaceutical companies, contract research organizations, and supporting providers to build strong, collaborative relationships.
The Greater Tattnall Chamber of Commerce (GTCC) is excited to announce the appointment of Dusty West as its new GTCC Jr. Board Director. Dusty, a lifelong Tattnall County resident, brings a wealth of experience and community involvement to the role. Susan G. Komen Breast Cancer Walk planned for Ludowici.
Enter search term . HealthLeaders Magazine. 2024 ; 2023 ; 2022 ; 2021 ; 2020 ; 2019 ; 2018 ; 2017 ; 2016 ; 2015 ; 2014 ; 2013
